Category: DRUG TRIAL
Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients
Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’
AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.
15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)
Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.
Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review
The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...
New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status
Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...
Ovarian Cancer Drug Zejula Shows Historical Results in Combination for Hard-to-Treat Cancer
KEY POINTS Zejula plus Keytruda improved the clinical benefits significantly in difficult-to-treat ovarian cancer patients than any one of them ...
Merck’s New Class of Drugs Shows Potential against Resistant Cancers
KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...
8 Most Promising Vaccines Under Development (2018)
KEY POINTS Here are some of the most promising vaccines on their way in 2018. Vaccines protect against a large ...
Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer
KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor. Last year, lorlatinib had received Breakthrough Therapy designation from the ...
Lupin & Yoshindo’s First Enbrel Biosimilar Targets Regulatory Approval
KEY POINTS YL Biologics announced the successful clinical outcome of YLB113- biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® ...